Effect of combined oral contraceptive use on serum 25-hydroxy vitamin D levels and ultrasound parameters in patients with polycystic ovary syndrome

Basit Öğe Kaydı
dc.authoridKosus, Nermin/0000-0003-2390-9498|NAMLI KALEM, MUBERRA/0000-0002-2316-5495
dc.contributor.authorKalem, Mueberra Namli
dc.contributor.authorHizli, Deniz
dc.contributor.authorKamalak, Zeynep
dc.contributor.authorKosus, Aydin
dc.contributor.authorKosus, Nermin
dc.contributor.authorTurhan, Nilgun
dc.contributor.authorKafali, Hasan
dc.date.accessioned2025-10-24T18:09:44Z
dc.date.available2025-10-24T18:09:44Z
dc.date.issued2016
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractPurpose: To investigate if there is an effect of combined oral contraceptive (COC) use on serum 25-hydroxy vitamin D [25(OH)D] levels in patients with polycystic ovary syndrome (PCOS). Methods: PCOS was defined by the 2003 Rotterdam criteria. All patients with PCOS were treated with a COC containing 0.035 mg ethinylestradiol and 2 mg cyproterone acetate for 6 months. Serum 25(OH)D levels, HOMA-IR, ovarian volume and antral follicule count were measured before and after the treatment. Results: The median 25(OH)D levels were 9.40 (range 4.40-24.50) mu g/l and 7.00 (5.00-13.50) mu g/l before and after COC use, respectively. Serum 25(OH)D levels decreased after the treatment; however, the difference was not statistically significant (p = 0.055). Conclusion: This study seems to be the first prospective trial revealing the effect of COC use on serum 25(OH)D levels in women with PCOS. Although the decrease in serum 25(OH)D levels in patients with PCOS with the use of COC alone, did not reach to statistically significance level after 6 months treatment with COC.
dc.identifier.doi10.3109/09513590.2015.1113251
dc.identifier.endpage284
dc.identifier.issn0951-3590
dc.identifier.issn1473-0766
dc.identifier.issue4
dc.identifier.pmid26654523
dc.identifier.scopus2-s2.0-84949553551
dc.identifier.scopusqualityQ2
dc.identifier.startpage281
dc.identifier.urihttps://doi.org/10.3109/09513590.2015.1113251
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3792
dc.identifier.volume32
dc.identifier.wosWOS:000373822700006
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofGynecological Endocrinology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjecthormonal; insulin resistance; polycystic ovary syndrome; Contraception
dc.titleEffect of combined oral contraceptive use on serum 25-hydroxy vitamin D levels and ultrasound parameters in patients with polycystic ovary syndrome
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu